Status of hepatitis B virus and hepatitis C elimination in Singapore: a call for action.
作者信息
Wong Yu Jun, Huang Daniel
机构信息
Department of Gastroenterology and Hepatology, Changi General Hospital, Singapore.
Duke-NUS Medical School, Singapore.
出版信息
Singapore Med J. 2025 Jul 1;66(7):376-378. doi: 10.4103/singaporemedj.SMJ-2025-142. Epub 2025 Jul 24.
Abstract
摘要
相似文献
1
Status of hepatitis B virus and hepatitis C elimination in Singapore: a call for action.新加坡乙肝和丙肝消除现状：行动呼吁
Singapore Med J. 2025 Jul 1;66(7):376-378. doi: 10.4103/singaporemedj.SMJ-2025-142. Epub 2025 Jul 24.
2
Canadian Association for the Study of the Liver Single Topic Conference on Hepatitis B Virus: 'Progress toward hepatitis B elimination in Canada'.加拿大肝脏研究协会乙型肝炎病毒单主题会议：“加拿大在消除乙型肝炎方面取得的进展”
Can Liver J. 2024 Aug 28;7(3):385-411. doi: 10.3138/canlivj-2024-0014. eCollection 2024 Aug.
3
From Education to Action-The Impact of Hepatitis C Micro-Elimination Education on Healthcare Provider Confidence and Linkage to Care: A Quasi-Experimental Study.从教育到行动——丙型肝炎微消除教育对医疗服务提供者信心及与护理联系的影响：一项准实验研究
Health Sci Rep. 2025 Jul 11;8(7):e71039. doi: 10.1002/hsr2.71039. eCollection 2025 Jul.
4
Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups.欧盟/欧洲经济区国家的乙型/丙型肝炎：对高危人群患病率的系统评价。
BMC Infect Dis. 2018 Feb 12;18(1):79. doi: 10.1186/s12879-018-2988-x.
5
Progress Toward Hepatitis C Virus Elimination among People Living with HIV-Hepatitis C Virus Coinfection in Canada.加拿大艾滋病毒-丙型肝炎病毒合并感染患者中丙型肝炎病毒消除进展情况。
Can Liver J. 2025 Feb 25;8(1):49-62. doi: 10.3138/canlivj-2024-0042. eCollection 2025 Feb.
6
How nurses contribute to the elimination of hepatitis B? A systematic review and meta-analysis.护士如何为消除乙型肝炎做出贡献？系统评价和荟萃分析。
Int J Nurs Stud. 2024 Jan;149:104622. doi: 10.1016/j.ijnurstu.2023.104622. Epub 2023 Oct 12.
7
Prevalence and factors associated with hepatitis B and C virus infections among female Sex workers in Ethiopia: Results of the national biobehavioral Survey, 2020.2020 年埃塞俄比亚全国生物行为调查：女性性工作者中乙型和丙型肝炎病毒感染的流行情况及相关因素。
PLoS One. 2022 Dec 30;17(12):e0269510. doi: 10.1371/journal.pone.0269510. eCollection 2022.
8
Hepatitis B vaccine effectiveness among vaccinated children in Africa: a systematic review and meta-analysis.非洲接种儿童乙型肝炎疫苗的有效性：系统评价和荟萃分析。
BMC Pediatr. 2024 Feb 28;24(1):145. doi: 10.1186/s12887-024-04557-w.
9
Development and evaluation of a simple treatment eligibility score (HEPSANET) to decentralise hepatitis B care in Africa: a cross-sectional study.开发和评估一种简单的治疗资格评分（HEPSANET），以在非洲分散乙型肝炎的护理：一项横断面研究。
Lancet Gastroenterol Hepatol. 2024 Apr;9(4):323-332. doi: 10.1016/S2468-1253(23)00449-1. Epub 2024 Feb 15.
10
The global and regional prevalence of hepatitis C and B co-infections among prisoners living with HIV: a systematic review and meta-analysis.全球和区域范围内，合并感染 HIV 的囚犯中丙型肝炎和乙型肝炎的流行情况：系统评价和荟萃分析。
Infect Dis Poverty. 2021 Jul 1;10(1):93. doi: 10.1186/s40249-021-00876-7.
本文引用的文献
1
Real-World Evaluation of Point-of-Care Testing for Hepatitis C Antibodies: Navigating Hepatitis C Elimination Effort.
J Viral Hepat. 2025 Apr;32(4):e14039. doi: 10.1111/jvh.14039. Epub 2024 Nov 22.
2
Hepatitis C elimination in Singapore: Current status and future directions.
J Gastroenterol Hepatol. 2025 Jan;40(1):339-340. doi: 10.1111/jgh.16773. Epub 2024 Oct 23.
3
Global epidemiology, natural history, maternal-to-child transmission, and treatment with DAA of pregnant women with HCV: a systematic review and meta-analysis.丙型肝炎病毒感染孕妇的全球流行病学、自然史、母婴传播及直接抗病毒药物治疗：一项系统评价和荟萃分析
EClinicalMedicine. 2024 Jul 13;74:102727. doi: 10.1016/j.eclinm.2024.102727. eCollection 2024 Aug.
4
Minimal monitoring is a safe but underutilised strategy for hepatitis C virus management in Singapore.在新加坡，最小化监测是丙型肝炎病毒管理中一种安全但未得到充分利用的策略。
Ann Acad Med Singap. 2023 Jun 27;52(6):321-323. doi: 10.47102/annals-acadmedsg.202347.
5
Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma.抗病毒治疗在乙型肝炎病毒和丙型肝炎病毒相关肝细胞癌切除术后的应用及 10 年结果。
J Clin Oncol. 2024 Mar 1;42(7):790-799. doi: 10.1200/JCO.23.00757. Epub 2024 Jan 4.
6
Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.直接作用抗病毒药物经治慢性丙型肝炎病毒感染者索磷布韦/维帕他韦/沃士韦治疗结局的系统评价和荟萃分析。
Viruses. 2023 Jun 30;15(7):1489. doi: 10.3390/v15071489.
7
Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study.真实世界中肝硬化丙型肝炎患者接受蛋白酶抑制剂直接抗病毒药物治疗的结局：REAL-C 研究。
Hepatol Int. 2023 Oct;17(5):1150-1161. doi: 10.1007/s12072-023-10547-4. Epub 2023 Jun 5.
8
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.抗病毒治疗可大幅降低处于不确定阶段的慢性乙型肝炎感染患者患肝癌的风险。
Hepatology. 2023 Nov 1;78(5):1558-1568. doi: 10.1097/HEP.0000000000000459. Epub 2023 May 16.
9
Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis.索磷布韦/维帕他韦联合或不联合利巴韦林治疗丙型肝炎基因3型代偿期肝硬化的疗效与安全性：一项荟萃分析。
World J Hepatol. 2022 Jun 27;14(6):1248-1257. doi: 10.4254/wjh.v14.i6.1248.
10
Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry.索磷布韦/维帕他韦/伏西瑞韦在既往接受过NS5A抑制剂治疗的丙型肝炎患者中的治疗结果：来自亚洲多中心注册研究的真实世界数据
J Gastroenterol Hepatol. 2022 Aug;37(8):1642-1644. doi: 10.1111/jgh.15918. Epub 2022 Jun 30.
Zotero 插件